MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT - In a regulatory update submitted to the Indian Stock Exchanges, Mumbai headquartered Glenmark Pharmaceuticals Ltd said of having received USFDA (US Food and Drugs Administration) nod to market medicine to treat obesity and overweight related disorders.
In a company press-release as submitted to the Indian Bourses, titled - "Glenmark Pharmaceuticals receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg" it further read that, Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Metformin Hydrochloride Extended‐Release Tablets USP, 500 mg and 1000 mg, the generic version of Glumetza®1 Extended‐Release Tablets, 500 mg and 1000 mg, of Salix Pharmaceuticals Inc.
According to IQVIA™ sales data for the 12‐month period ending September 2019, the Glumetza® Tablets, 500 mg and 1000 mg market2 achieved annual sales of approximately $226.7 million.
Glenmark’s current portfolio consists of 164 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
To read more, please CLICK here
FOLLOW US ON :-
- BLOG : http://datelinegujarat.blogspot.com/
- FACEBOOK : https://facebook.com/dateline.gujarat
- GOOGLE+ : https://plus.google.com/110800330482982580799
- INSTAGRAM : https://www.instagram.com/datelinegujarat/
- LINKEDIN : https://in.linkedin.com/in/dateline-gujarat-7681885a
- TELEGRAM : https://t.me/DATELINEGUJARATDOTCOM
- TWITTER : https://twitter.com/DatelineGujarat
- YOUTUBE : https://www.youtube.com/user/DatelineGujarat
- WEBSITE (URL) : https://datelinegujarat.com
No comments:
Post a Comment